FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder

The U.S. Food and Drug Administration (FDA) on Friday approved Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) for adult patients with bullous pemphigoid (BP), a rare, chronic autoimmune skin disorder.

BP primarily affects elderly patients and is characterized by intense itch, painful blisters and lesions, and skin reddening. It can be chronic and relapsing with underlying type 2 inflammation.

The blisters and rash can form over much of the body and cause the skin to bleed and break down, making patients more prone to infection.

Also Read: Regeneron, Sanofi Stock Falls After ...